ZSSF treatment dramatically reduced anxiety-like behaviors, exerted sedative–hypnotic effects, increased hippocampal 5-HT and 5-HTP, and enhanced intestinal barrier function through inhibiting colon ZO-1, Claudin-1, and Occludin expression and reducing TNF-α, IL-6, and IL-1β levels. The gene discussed is OCLN; the disease is Anxiety.